Drug Profile
Eltrekibart - Eli Lilly and Company
Alternative Names: CXCR1/2L mAb - Eli Lilly and Company; LY-3041658Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Anti-inflammatories; Antibodies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Chemokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hidradenitis suppurativa
- No development reported Skin disorders
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Hidradenitis suppurativa(In volunteers) in Singapore (SC, Injection)
- 23 Oct 2023 Eli Lilly and Company initiates enrolment in a phase II trial for Hidradenitis suppurativa in USA (SC) (NCT06046729)
- 21 Sep 2023 Eli Lilly and Company plans a phase II trial for Hidradenitis suppurativa (SC) (NCT06046729)